Tagomics Ltd., known for its groundbreaking work in biomarker discovery and diagnostics, has announced a strategic partnership with Agilent Technologies, a key player in genomic tools, to embark on a co-marketing initiative. This collaboration will enable selected clients to access the combined advanced technologies of both companies through an exclusive access program operated from Tagomics’ Cambridge-based lab.
Tagomics has introduced an innovative multiomics platform called Interlace, designed to extract disease-related DNA biomarkers from diverse biological sources. The technology employs a specialized method of epigenetic profiling, enriching unmethylated DNA for analysis without altering the DNA sequence. The Interlace platform integrates whole-genome sequencing or targeted sequencing, and its sophisticated bioinformatics and machine-learning software facilitate a single, affordable, minimal-input, and automated procedure for analyzing genetic, epigenetic, and fragmentomic characteristics.
Agilent Technologies offers complete solutions for targeted genomic profiling. The SureSelect Library Preparation and Target Enrichment System, paired with the SureSelect Cancer panels, efficiently identifies a comprehensive range of somatic variants in solid tumors, including single nucleotide variants (SNVs), copy number variants (CNVs), insertions/deletions (indels), translocations (TLs), gene fusions, alongside immuno-oncology biomarkers Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI).
Tagomics has effectively merged Agilent’s SureSelect XT HS2 Library Preparation and Target Enrichment System within its multiomic processes, enabling extensive genomic and epigenomic insight via a unified workflow.
To highlight the synergy of their amalgamated approaches, Tagomics has forged a co-marketing arrangement with Agilent Technologies, unveiling a technology access program that permits select customers to leverage the enhanced capabilities before the broader market release. This facilitates a deeper understanding of disease mechanisms, paving the way for innovative diagnostic and treatment strategies.
Dr. Jack Kennefick, CEO and co-founder of Tagomics, expressed: “We’re thrilled to collaborate with Agilent Technologies to deliver the integrated strengths of our platforms in Tagomics’ Interlace multiomic workflow to select customers. This partnership aims to provide customers with enriched biological insights, accelerating the creation of groundbreaking diagnostic and therapeutic solutions.”
Ronda Allen, General Manager of Genomics at Agilent Technologies, remarked: “Through our agreement, our clients will gain access to Tagomics’ Interlace platform and advanced bioinformatics tools, allowing genetic and comprehensive epigenomic profiling concurrently. Integrating our SureSelect Library Preparation and Target Enrichment System into Tagomics’ process enhances our existing genomic profiling capabilities, supporting our goal to advance scientific progress.”